Developing new drugs from annals of Chinese medicine

被引:16
作者
Bian, Zhaoxiang [1 ]
Chen, Shilin [2 ]
Cheng, Chungwah [1 ]
Wang, Jun [1 ]
Xiao, Haitao [1 ]
Qin, Hongyan [1 ]
机构
[1] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Acad Med Sci, Inst Med Plant Dev, Beijing 100094, Peoples R China
关键词
New drug development; Clinical trial; Anecdote; Case report; Chinese medicine;
D O I
10.1016/j.apsb.2011.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Developing new pharmaceuticals requires massive amounts of time, money and efforts. The key step is how to find a safe and effective entity for a disease condition and how to develop it as new drug effectively. Unfortunately, the FDA's rate of approving new entities has declined dramatically in the last three decades. There is a strong need to review the current strategy and to optimize process in developing new drugs, both to shorten the process and increase the success rate. Chinese medicine has used natural products to treat patients for thousands of years, and Chinese medicine practitioners have chronicled the patients and treatment methods for thousands of years. There is much information that has not yet been used. The success stories of artimisinin and arsentic trioxide are wonderful examples of how the annals of Chinese medicine can provide leads for discovering new drugs. This paper argues that the annals of Chinese medicine are valuable and describes how they can be used in modern drug discovery. The major topics addressed are: (i) why Chinese medicine is a rich resource for finding new drugs; (ii) how to identify a potential valuable record from Chinese medicine annals; (iii) when a potential valuable record is identified from annals, how to proceed; and (iv) both why and how the approach used for chemical drugs should be revised for drugs based on the historical documents related to herbal medicine. In conclusion, we argue here that the annals of Chinese medicine offer not only a rich resource for new drugs, but also several centuries of patient data with regard to safety and efficacy, that in effect represent pilot studies. Acknowledging and using these data can shorten new drug discovery time and improve efficiency of the drug development process, bringing more effective, safe drugs to market much more quickly and cheaply. (C) 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and hosting by Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 2002, DIVINE FARMERS MAT M
[2]  
Bensky D, 1990, CHINESE HERBAL MED F
[3]  
Bian Zhao-Xiang, 2006, Zhong Xi Yi Jie He Xue Bao, V4, P120
[4]   Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome:: A systematic review [J].
Bian, Zhaoxiang ;
Wu, Taixiang ;
Liu, Liang ;
Miao, Jiangxia ;
Wong, Honfat ;
Song, Lisa ;
Sung, Joseph J. Y. .
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2006, 12 (04) :401-407
[5]   Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: Current situation and future development [J].
Bian Z. ;
Liu B. ;
Moher D. ;
Wu T. ;
Li Y. ;
Shang H. ;
Cheng C. .
Frontiers of Medicine, 2011, 5 (2) :171-177
[6]  
BROWN P W, 1950, Rocky Mt Med J, V47, P343
[7]  
Chen GQ, 1996, BLOOD, V88, P1052
[8]   Key factors in the rising cost of new drug discovery and development [J].
Dickson, M ;
Gagnon, JP .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :417-429
[9]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[10]  
FDA, 2000, FDA APPR CELL THER T